Compare LQDA & ALRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | ALRM |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2018 | 2015 |
| Metric | LQDA | ALRM |
|---|---|---|
| Price | $35.17 | $51.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | $37.40 | ★ $64.67 |
| AVG Volume (30 Days) | ★ 1.7M | 427.5K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.77 |
| EPS | N/A | ★ 2.36 |
| Revenue | $69,216,000.00 | ★ $991,770,000.00 |
| Revenue This Year | $904.79 | $8.53 |
| Revenue Next Year | $188.25 | $4.12 |
| P/E Ratio | ★ N/A | $22.14 |
| Revenue Growth | ★ 343.41 | 7.36 |
| 52 Week Low | $10.37 | $46.65 |
| 52 Week High | $35.54 | $68.54 |
| Indicator | LQDA | ALRM |
|---|---|---|
| Relative Strength Index (RSI) | 67.11 | 52.51 |
| Support Level | $32.11 | $51.00 |
| Resistance Level | $35.54 | $53.29 |
| Average True Range (ATR) | 1.50 | 0.93 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 92.26 | 34.14 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Alarm.com Holdings Inc has a cloud-based platform that offers an expansive suite of IoT solutions addressing world-wide opportunities in the residential, multi-family, small business and enterprise commercial markets. It has two reportable segments: Alarm.com & Other. The Alarm.com segment represents the cloud-based Software platforms for intelligently connected property & related solutions. The other segment is focused on researching, developing & offering residential & commercial automation solutions & energy management products & services in adjacent markets. The majority of revenue is from the Alarm.com segment. The platform allows home & business owners to secure their properties and automate & control an array of connected devices.